Three Rivers Pharmaceuticals recently announced U.S. Food and Drug Administration (FDA) approval for its Ribasphere® (ribavirin, USP) Tablets 600 mg, 400 mg, and 200 mg in combination with interferon alfa-2a for the treatment of hepatitis C (HCV).

While interferon plus ribavirin combination therapy is commonly used in HCV patients, this new FDA approval offers potential benefits such as improved efficacy and better patient adherence to treatment. “Ribasphere® Tablets 600 mg, 400 mg, and 200 mg provide the patient and physician an opportunity to significantly reduce the number of tablets a patient has to take each day,” said Three Rivers President and CEO Donald J. Kerrish, R.Ph. “Three Rivers believes that this has the potential to lead to better patient compliance and improved patient outcomes.”

Three Rivers, which is based Cranberry Township, PA, will market and distribute the product with it’s partner PAR Pharmaceuticals of Spring Valley, NY.

Source: Three Rivers Pharmaceuticals press release dated December 5, 2005